Can a new biologic erase traces of myeloma and delay transplant?

This phase 2 trial is testing whether linvoseltamab, an investigational biologic given by infusion, can turn minimal residual disease (MRD) from positive to negative in people with newly diagnosed multiple myeloma. Participants have already received initial combination therapy but still have detectable MRD, meaning a small number of cancer cells remain. The goal is to see if linvoseltamab can deepen the response, extend the time the disease is controlled, and potentially delay the need for a stem cell transplant. The study will also monitor side effects and how long any MRD-negative state lasts.